American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

STEAM—Sequential versus Concurrent FOLFOXIRI/Bevacizumab in Metastatic Colorectal Cancer

ASCO 2016 – GI

Avelumab in Advanced Gastric or Gastroesophageal Cancer

ASCO 2016 – GI

Results from the phase 1b JAVELIN study of the anti–PD-L1 monoclonal antibody avelumab in patients with advanced gastric or gastroesophageal junction cancer, stratified based on the level of PD-L1 expression. Read More ›

Nivolumab Monotherapy in Advanced Gastroesophageal or Gastric Cancer

ASCO 2016 – GI

Results of an open-label phase 1/2 study evaluating the safety and efficacy of nivolumab monotherapy for patients with advanced gastroesophageal or gastric cancer. Read More ›

Pembrolizumab in PD-L1+ Advanced Esophageal Carcinoma

ASCO 2016 – GI

Results of the phase 1b KEYNOTE-028 study of pembrolizumab in PD-L1+ advanced esophageal carcinoma. Read More ›

The Role of the mTOR Pathway in Cancer Stem Cells in Esophageal Cancer

ASCO 2016 – GI

Investigation of the role of the mTOR pathway on the stemness of a putative cancer stem- cell population in esophageal cancer. Read More ›

Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

ASCO 2016 – GI

Results from RAINBOW, a randomized phase 3 trial of the safety and efficacy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. Read More ›

Panitumumab in Wild-Type KRAS and RAS Metastatic Colorectal Cancer

ASCO 2016 – GI

Results from an open-label, randomized phase 3 trial evaluating the effects of panitumumab plus best supportive care versus best supportive care alone in chemorefractory, wild-type KRAS exon 2 and wild-type RAS metastatic colorectal cancer. Read More ›

First-Line Demcizumab/Gemcitabine ± Nab-Paclitaxel in Pancreatic Cancer

ASCO 2016 – GI

Results from a phase 1b study of the anticancer stem-cell agent demcizumab plus gemcitabine with or without nab-paclitaxel in the first-line treatment of patients with pancreatic cancer. Read More ›

BBI608/Gemcitabine/Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma

ASCO 2016 – GI

Results from a phase 1b study of the cancer stem-cell pathway inhibitor BBI608 plus gemcitabine and nab-paclitaxel in treating patients with metastatic pancreatic ductal adenocarcinoma. Read More ›

Tremelimumab plus TACE, RFA, or Cryoablation in Hepatocellular Carcinoma or Biliary Tract Carcinoma

ASCO 2016 – GI

Results of a clinical trial to determine if transcatheter chemoembolization, radiofrequency ablation, and cryoablation can enhance the effect of the CTLA-4 inhibitor tremelimumab in treating patients with hepatocellular carcinoma or biliary tract carcinoma. Read More ›

Page 22 of 31

19
20
21
22
23
24
25

Conference Coverage Proudly Presented by

American Health & Drug Benefits

Journal of Hematology Oncology Pharmacy

Journal of Oncology Navigation & Survivorship

Oncology Practice Management

Personalized Medicine in Oncology

The Oncology Nurse–APN/PA

The Oncology Pharmacist

Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications